Furthermore, plasma lncRNAs Growth Arrest-Specific 5 (GAS5) and SOX2OT combined as dual-gene diagnostic model distinguished NSCLC from benign nodules with an AUC of 0.82 (77%–87%), with 83.8% sensitivity and 81.4% specificity (66). The gene discussed is GAS5; the disease is non-small cell lung carcinoma.